Jyong Biotech Ltd. · NASDAQ:MENS
Jyong Biotech — IPO Roadshow (February 2025)
35 slides from Jyong Biotech's IPO roadshow presentation, Feb 7, 2025
Slide 1: Jyong Biotech Ltd. February 2025 Free Writing Prospectus
Jyong Biotech Ltd. Fqbruary 2025 Issuqr Frqq Writing Prospqctus datqd Fqbruary 07, 2025 Filqd pursuant to Rulq 433 of thq Sqcuritiqs Act of 1933, as amqndqd Rqlating to Prqliminary Prospqctus datqd Fqbruary 6, 2025 Rqgistration No. 333 - 277725
Slide 2: Disclaimer
Disclaimer This prqsqntation has bqqn prqparqd by Jyong Biotqch Ltd . (thq “Company”) solqly for informational purposqs . Thq information includqd hqrqin in this prqsqntation has not bqqn indqpqndqntly vqrifiqd . No rqprqsqntations, warrantiqs or undqrtakings, qxprqss or impliqd, arq madq by thq Com
Slide 3: Preliminary Offering Summary
Preliminary Offering Summary • Jyong Biot Q ch Ltd. Issuer • Nasdaq Global Mark Q t/ MENS Listing / Ticker • Initial Public Off Q ring (In Progr Q ss) Offering Type • 2,328,921 ordinary shar Q s (b Q for Q Q x Q rcising ov Q r - allotm Q nt option メ Shares Offered • 349,338 ordinary shar Q s (15% of
Slide 4: Table of contents
Table of contents 01 Company Overview - Core Products 02 Industry Overview – Potential market 03 Investment Highlights section section section 06 05 04 Appendix Financials Growth Strategies section section section Jyong Biot Q ch Ltd. | Pag Q 4
Slide 5: Company Overview - Core Products
Company Overview - Core Products 01 Jyong Biot Q ch Ltd. | Pag Q 5
Slide 6: We Are a Science-Driven Biotech Company Based in Taiwan
• Sp Q cializ Q in th Q tr Q atm Q nt of urinary syst Q m dis Q as Q s • Committ Q d to d Q v Q loping and comm Q rcializing innovativ Q and diff Q r Q ntiat Q d n Q w drugs • Focus on th Q mark Q ts of th Q U.S., th Q EU and Asia (primarily Taiwan and mainland China) Jyong Biot Q ch Ltd. | Pag Q 6
Slide 7: Core Drug Candidate Pipeline
Core Drug Candidate Pipeline Jyong Biot Q ch Ltd. | Pag Q 7 Company Overview Industry Overview Investment Highlights Growth Strategies Financials IC • IC is also an important drug candidat Q that utiliz Q s nanocarri Q rs to Q nhanc Q bioavailability for intrav Q nous and intrav Q sical administrati
Slide 8: Validated R&D Capabilities and Proprietary Platform
Validated R&D Capabilities and Propietary Platform H Q althy pip Q lin Q of drug candidat Q s at clinical stag Q and pr Q clinical stag Q Tr Q atm Q nt for: • B Q nign prostat Q hyp Q rplasia/low Q r urinary tract symptoms (BPH/LUTS) • Prostat Q canc Q r pr Q v Q ntion • Int Q rstitial cystitis • Ea
Slide 9: In-house Capabilities to Manufacture Drug Candidates
Company Overview Industry Overview Investment Highlights Growth Strategies Financials In - house Capabilities to Manufacture Drug Candidates • Yilan L Q tz Q r Pharmac Q utical Factory authoriz Q d by TFDA to conduct drug manufacturing, packaging, laboratory op Q rations, transportation and storag Q
Slide 10: Industry Overview – Potential market for MCS-2
Industry Overview – Potential market for MCS - 2 02 Jyong Biot Q ch Ltd. | Pag Q 10
Slide 11: Aging population and growing healthcare market
• Th Q world's growing and aging population is driving incr Q as Q d h Q althcar Q d Q mand and Q xp Q nditur Q • Th Q aging population r Q ach Q d 747.5 million in 2021, a 15.0% incr Q as Q from 2017. P Q opl Q ov Q r 55 y Q ars old totall Q d 14,374.6 million in 2020, growing at 2.3% annually • Gl
Slide 12: Global BPH Drugs Market
• Global BPH pr Q val Q nc Q ros Q from 88.4 million in 2017 to 94.2 million in 2020, a 6.5% incr Q as Q • BPH drugs mark Q t gr Q w from $3.7 billion in 2017 to $4.1 billion in 2020, proj Q ct Q d to r Q ach $9.8 billion in 2026 • Factors driving mark Q t growth includ Q aging population, rising ob
Slide 13: Global PCP Drugs Market
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biot Q ch Ltd. | Pag Q 13 Sourc Q : Frost & Sullivan Global PCP Drugs Market - Pr Q val Q nc Q incr Q as Q d from 10.0 million (2017) to 11.2 million (2020) globally (3.9% CAGR) - Mark Q t siz Q : $12.6 billi
Slide 14: Market Drivers, Future Trends, Entry Barriers
1. Shift from mark Q ting - focus Q d to valu Q - focus Q d: pharma compani Q s must prioritiz Q R&D and innovation ov Q r Q xc Q ssiv Q mark Q ting Q xp Q ns Q s to driv Q industry growth 2. Incr Q asing d Q mand for botanical drugs: natural product tr Q nds will boost th Q n QQ d for plant - d Q r
Slide 15: Investment Highlights
Investment Highlights 03 Jyong Biot Q ch Ltd. | Pag Q 15
Slide 16: MCS-2 (BPH/LUTS Treatment)
MCS - 2 (BPH/LUTS Treatment) • BPH/LUTS is a common urinary tract dis Q as Q in middl Q - ag Q d m Q n. Curr Q ntly, th Q r Q ar Q s Q v Q ral drugs to tr Q at BPH/LUTS, how Q v Q r, only about 60 - 70 p Q rc Q nt of pat Q nts tr Q at Q d can hav Q symptom improv Q d. Th Q r Q for Q , curr Q nt BPH/
Slide 17: Safety Issues: Current BPH/LUTS Drugs
Safety Issues: Current BPH/LUTS Pharmacologic Class Chemical Name Manufacturer Adverse Effects alpha - 1 adrenergic blockers Tamsulosin Ast Q llas Pharma (Japan) Orthostatic hypot Q nsion, Q jaculation disord Q r, nasal cong Q stion, malais Q , syncop Q , tachycardia, naus Q a, indig Q stion/gastral
Slide 18: Phase III Clinical Trials Safety Profile
Phase III Clinical Trials US Total Plac Q bo MCS - 2 (API - 1) 30 mg/day MCS - 2 (API - 1) 15 mg/day N=274 N (%) N=76 N (%) N=156 N (%) N=42 N (%) 108 (39.4) 33 (43.4) 59 (37.8) 16 (38.1) Adverse Event (AE) 41 (15.0) 14 (18.4) 21 (13.5) 6 (14.3) Related AE 3 (1.1) 2 (2.6) 1 (0.6) 0 (0.0) Serious Adv
Slide 19: Diverse Drug Portfolio And Validated R&D Capabilities
Company Overview Industry Overview Investment Highlights Growth Strategies Financials MCS - 2 Inv Q ntion pat Q nts Trad Q marks Four phase III clinical trials in the U.S. and Taiwan. 31 invention patents in 19 territories. 58 trademarks in more than 46 territories. Innovativ Q Propri Q tary R&D Pla
Slide 20: Key Issued Invention Patents in Multiple Territories
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Key Issued Invention Patents in Multiple Territories Expiration date of patent right Country ( Owned Patent number) Patent* ~2034/12 Taiwan Inv Q ntion ~2034/12 South Kor Q an Inv Q ntion ~2034/12 Singapor Q Inv Q
Slide 21: Integrated In-house Capabilities for Pharmaceutical Innovation
Integrated In - house Capabilities That Well Position Us For Pharmaceutical Innovation From Bench To Bedside Company Overview Industry Overview Investment Highlights Growth Strategies Financials Our l Q ad candidat Q , MCS - 2, is a plant - d Q riv Q d drug sp Q cifically d Q sign Q d for tr Q ating
Slide 22: Highly Experienced Management Leads R&D
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biot Q ch Ltd. | Pag Q 22 Highly Experienced Management Leads R&D Fu - Feng Kuo - Dir Q ctor sinc Q D Q c Q mb Q r 2018 - Chairwoman of th Q board of dir Q ctors and CEO - Found Q r of H Q alth Ev Q r Bio - T
Slide 23: Management Team with Great Vision
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Management Team with Great Vision Alfred Ying - Ov Q r 20 y Q ars of capital mark Q ts Q xp Q ri Q nc Q - Exp Q rtis Q in corporat Q financ Q , capital raising, financ Q , and accounting - Curr Q ntly CFO of H Q al
Slide 24: Board Directors
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Jyong Biot Q ch Ltd. | Pag Q 24 Board Directors Hung - Shu Fan - Prof Q ssor and associat Q d Q an at Fu J Q n Catholic Univ Q rsity - Ind Q p Q nd Q nt dir Q ctor of Taiwan S Q miconductor Co., Ltd. and Tig Q rair
Slide 25: Growth Strategies
Growth Strategies 04 Jyong Biot Q ch Ltd. | Pag Q 25
Slide 26: MCS-2 Commercialization
ೣ D Q dicat Q d sal Q s and mark Q ting t Q am for pip Q lin Q drug candidat Q s, including MCS - 2 ೣ Exp Q ri Q nc Q d t Q am in Taiwan, s QQ king local pharmac Q utical partn Q rships in oth Q r t Q rritori Q s ೣ S Q nior product manag Q r l Q ading MCS - 2 strat Q gi Q s ೣ Positiv Q f QQ dback fr
Slide 27: Deepen pipeline and advance other drug candidates
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Deepen pipeline in existing therapeutic areas with new drugs • Anchor th Q rap Q utic focus ar Q as with comp Q titiv Q drug products and Q xpand around th Q m • Fost Q r tal Q nt growth and r Q cruit high - qualit
Slide 28: Build Commercial Infrastructure
Build Commercial Infrastructure Company Overview Industry Overview Investment Highlights Growth Strategies Financials ೣ Maximiz Q pati Q nt r Q ach for futur Q products, sp Q cifically MCS - 2 ೣ Establish d Q dicat Q d sal Q sforc Q in th Q U.S., EU, and Asia (Taiwan and mainland China) ೣ Explor Q c
Slide 29: Financials
Financials 05 Jyong Biot Q ch Ltd. | Pag Q 29
Slide 30: Selected Financial Information (Unaudited)
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Selected Financial Information (Unaudited) - $1,109 - $951 Half Year Ended 06/2023 Half Year Ended 06/2024 Total Op Q rating Exp Q ns Q s USD Thousand $1,719 $99 Half Year Ended 06/2023 Half Year Ended 06/2024 Cash
Slide 31: Research and Development Expenses
Company Overview Industry Overview Investment Highlights Growth Strategies Financials Research and Development Expenses ೣ This tabl Q s Q ts forth a br Q akdown of th Q major compon Q nts of our r Q s Q arch and d Q v Q lopm Q nt Q xp Q ns Q s in absolut Q amounts and as a p Q rc Q ntag Q of our tot
Slide 32: Unaudited Interim Condensed Consolidated Balance Sheets
APPENDIX – UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (in thousand US$) As of June 30, 2024 As of December 31, 2023 Unaudited Audited ASSETS Current Assets 96 $ 177 $ Cash 3 1,565 R Q strict Q d cash 101 97 Pr Q paym Q nts and oth Q r curr Q nt ass Q ts 200 1,839 Total current assets 6,
Slide 33: Statements of Operations and Comprehensive Loss
APPENDIX – UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousand US$) For the six months ended June 30, 2024 2023 Unaudited Unaudited Operating expenses ) (499 $ ) (538 $ R Q s Q arch and d Q v Q lopm Q nt ) (21 ) (22 S Q lling and mark Q ting ) (431 )
Slide 34: Statements of Cash Flows
APPENDIX – UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousand US$) For the six months ended June 30, 2024 2023 Unaudited Unaudited Cash flows from operating activities ) (1,326 $ ) (1,742 $ N Q t loss ) (2,773 ) (1,292 Net cash used in operating activities Cash flows from
Slide 35: Thanks
Thanks Company Jyong Biotech Ltd. s Q rvic Q s@h Q biot Q ch.com +886 (2) 2732 5205 www.h Q alth Q v Q rbiot Q ch.com Underwriter Jos Q ph Ston Q Capital, LLC 585 St Q wart Av Q nu Q , Unit L60 - C Gard Q n City, N Q w York 11530 T Q l: 888 - 302 - 5548 Email: corporat Q financ Q @Jos Q phston Q cap